MCCORMICK FRANK
SEC Form 4 insider trading activity
MCCORMICK FRANK has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Jun 24, 2026.
On the most recent filing, MCCORMICK FRANK is listed as Director at BridgeBio Pharma, Inc. Inside the rolling window, MCCORMICK FRANK reported no open-market purchases and 2 open-market sales totaling $13.3M in BBIO. The largest disclosed transaction in the window is a sale of 198,359 BBIO shares on Oct 29, 2025, worth $13.2M.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$13.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 5, 2025 | BBIO | Sale | $3.9M |
Frequently asked questions
How many SEC Form 4 filings has MCCORMICK FRANK made?
MCCORMICK FRANK has filed 4 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.
Which companies does MCCORMICK FRANK trade?
MCCORMICK FRANK has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was MCCORMICK FRANK's most recent SEC Form 4 filing?
MCCORMICK FRANK's most recent SEC Form 4 filing on Tracefour is dated Jun 24, 2026.
What is MCCORMICK FRANK's total buy and sell value in the current window?
Inside the rolling retention window, MCCORMICK FRANK bought $0 and sold $13.3M based on SEC Form 4 filings.
What was MCCORMICK FRANK's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 198,359 BBIO shares on 2025-10-29, worth $13.2M, per SEC Form 4 filings.